Your institution may have access to this item. Find your institution then sign in to continue.
Title
Dupilumab (Dupixent) for Asthma.
Abstract
This Medical Letter review summarizes doses and formulations of dupilumab (Dupixent), a subcutaneously injected monoclonal antibody add-on maintenance treatment approved for patients aged 12 years or older with moderate to severe asthma with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.